Skip to main content
S&P 5007,757.17+0.58%DOW52,856.09+0.69%NASDAQ26,702.86+1.05%BTC$84,192.00+1.31%ETH$2,474.04+0.74%GOLD$4,133.80-0.39%OIL$98.06+0.94%
Smart Investors Daily
SID Premium
YD

NASDAQ · YDES

YD Bio Limited Ordinary Shares

Healthcare · Biotechnology

$5.77

Down-$0.07 (-1.20%)

Updated Oct 22, 2026, 7:57 AM

SID Score

3.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
894.92M
P/E ratio
-14.54
Dividend yield
0.00%
52-week range
$1.70 – $8.77
Volume
144.1K
Avg. volume
92.84K

Price performance · YDES

YDES price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 21, 2026

YDES closed at $5.77 after 21 trading sessions, up 78.64% for the selected period.

Last close
$5.77
Period change
+78.64%
Period low
$3.23
Period high
$8.11
Daily close
View OHLC price history
YDES OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 21, 2026$5.89$6.30$5.5995$5.77144.1K
Oct 20, 2026$6.08$6.565$5.61$5.84178.14K
Oct 19, 2026$5.92$6.26$5.46$6.1292.52K
Oct 16, 2026$6.67$7.05$5.82$5.92153.37K
Oct 15, 2026$6.30$6.8699$6.30$6.7472.33K
Oct 14, 2026$6.16$6.47$6.0001$6.3620.35K
Oct 13, 2026$6.33$6.51$6.00$6.1023.6K
Oct 12, 2026$7.01$7.13$6.10$6.33138.13K
Oct 9, 2026$5.71$7.09$5.61$6.73207.79K
Oct 8, 2026$5.81$6.1999$5.53$5.79148.95K
Oct 7, 2026$6.22$6.38$5.6324$5.88135.93K
Oct 6, 2026$6.94$7.10$5.20$6.15439.69K
Oct 5, 2026$7.90$8.03$6.81$7.11258.51K
Oct 2, 2026$7.71$8.43$6.60$8.11546.62K
Oct 1, 2026$7.18$8.25$6.99$7.81267.88K
Sep 30, 2026$7.59$7.73$6.80$7.42205.69K
Sep 29, 2026$7.03$7.89$6.62$7.61349.71K
Sep 28, 2026$6.13$7.35$5.62$7.11508.32K
Sep 25, 2026$4.77$5.88$4.5475$5.73656.54K
Sep 24, 2026$3.26$5.41$3.26$4.773.17M
Sep 23, 2026$2.78$3.34$2.4201$3.23359.18K

Latest YDES news

The latest Smart Investors Daily articles mentioning YDES.

Stock researchCompany · Overview

YDES research

Overview

Company profile and research snapshot.

Company profile

YD Bio Ltd is a biopharmaceutical company focusing on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering innovative treatments for injuries, degenerative diseases, and immune disorders with potential for personalized medicine and tissue engineering.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 20, 2026

YD Bio and EG BioMed Partner with JoiiUp to Launch AI-Driven Cancer Risk Assessment for Corporate Wellness Programs

TAIPEI, Taiwan, and BOTHELL, Wash., Oct. 20, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection and ophthalmologic innovations, today announced a strategic collaboration with EG BioMed Co., Ltd., a Taiwan registered company and an affiliate of YD Bio (“EG BioMed”), and digital health provider JoiiUp. The partnership integrates an AI Cancer Risk Assessment (the “Assessment”), jointly develope

Benzinga · Oct 9, 2026

12 Health Care Stocks Moving In Friday's Intraday Session

Gainers Quantum-Si (NASDAQ:QSI) stock rose 30.3% to $1.59 during Friday's regular session. The company's market cap stands at $267.0 million. Nautilus Biotechnology (NASDAQ:NAUT) stock rose 26.09% to $2.29.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By